What ProFeme Treats: Main Uses and Benefits

ProFeme, which contains the progestin micronized progesterone, is generally applied across domains where additional symptomatic support is needed, primarily as a component of Menopausal Hormone Therapy (MHT). Combined hormone therapy is commonly used to help with conditions involving episodic or fluctuating manifestations, such as those related to systemic or localized discomfort and symptoms that become more disruptive during flare-ups.

Combining estrogen and a progestin may assist with easing symptom clusters that may become intense or disruptive, specifically to provide support that helps ease the overall symptom burden of hot flashes, night sweats, and urogenital discomfort. These uses are relevant across conditions presenting with systemic or localized discomfort, conditions associated with acute or disruptive episodes, and other hormone-related issues requiring progestin support.

For patients who still have their uterus, the progesterone component is considered relevant for supporting functional stability and easing symptoms linked to organ-specific functional stress that may be part of symptomatic management when using estrogen alone. This approach is applied in scenarios where additional management of discomfort is required, providing supportive relief when symptoms interfere with routine activities and contributes to improved comfort during periods of heightened symptoms. The patient-oriented benefit helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for symptoms related to physical discomfort

“This supportive symptomatic relief assists with maintaining functional stability during episodes of heightened discomfort.”

Who Can and Cannot Use ProFeme?

The population eligibility rules for ProFeme (progesterone cream) are determined by governmental regulatory bodies, focusing on strict contraindications and age-group restrictions.

Populations for Whom Use is Prohibited (Contraindications)

ProFeme is contraindicated and must not be used by individuals with certain pre-existing conditions:

Category	Prohibited Condition
Organ Function	Severe hepatic impairment or active liver disease.
Vascular History	Active or history of thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism) or severe thrombophlebitis.
Oncology	Known or suspected progesterone-sensitive malignant tumours (e.g., breast cancer).
Other	Hypersensitivity or allergy to progesterone or any ingredients, including almond oil; undiagnosed abnormal vaginal bleeding.

---

Age and Physiological Restrictions

Use of ProFeme is restricted based on life stage and developmental status:

• Pediatric Use: The product is not indicated for use in children, and safety data for this age group is insufficient.
• Lactation: Use is not recommended for women who are breastfeeding.
• Pregnancy: While generally not recommended, use may be restricted to the first trimester for specific indications, such as corpus luteum deficiency.

Conditional Use

Patients with certain comorbidities, such as kidney disease (renal dysfunction), epilepsy, migraine, asthma, or diabetes, require careful observation if ProFeme is used, due to the potential for fluid retention or metabolic changes.

Interactions with other medicines and products

ProFeme (progesterone) cream is a topical product, and its known interactions are categorized into those affecting local absorption and those involving systemic drug combinations.

Interactions Affecting Absorption

Topical products applied to the same area as ProFeme cream can interfere with its absorption into the skin. To maintain consistent absorption, it is important to avoid applying the following products to the application site:

• Perfume
• Deodorant
• Moisturizing creams or gels

Additionally, procedural constraints are necessary due to the topical route of administration. Patients are advised not to swim or shower until at least one hour after applying the cream to prevent the medicine from being washed away.

Drug-Drug Interactions

While specific interacting medicines are not listed in the available patient-focused regulatory information for ProFeme, a general advisory applies to all prescribed medicines. Users of ProFeme must inform all treating doctors, dentists, and pharmacists of its use before starting any other medication. This procedural step ensures that potential interactions with any other medications—including prescription, over-the-counter, or complementary products—can be evaluated and managed by a healthcare professional.

ProFeme modulates the RANK/RANKL/OPG system and targets the osteoclast lineage. The active compound acts as a direct inhibitor of the enzyme cathepsin K (CTSK). This molecular interaction restricts the proteolytic activity of mature osteoclasts, thereby limiting the enzymatic degradation of the organic bone matrix (collagen and non-collagenous proteins).

Concurrently, ProFeme influences the cytokine signaling cascade involving Receptor Activator of Nuclear Factor kappaB Ligand (RANKL) and Osteoprotegerin (OPG). This modulation affects the signal required for the differentiation, activation, and survival of osteoclast precursor cells. The drug exerts a dual mechanism by inhibiting CTSK function while also influencing the control of osteoclast formation. This combined action reduces overall osteoclast activity and maintains the physiological balance of bone remodeling. Ultimately, this cascade shifts the equilibrium of bone turnover toward bone formation.

ProFeme is a progesterone cream intended for transdermal administration to the skin. Standard guidelines define precise instructions covering dosing schedules and procedural conditions to ensure consistency in application.

Administration Scope	Official Instruction
Route of Administration	Transdermal application to clean, dry skin, typically on the inner forearm or upper thigh.
Dosing Measurement	The dose must be measured precisely using the graduated applicator supplied with the product. Standard starting doses are highly specific, such as 0.3 mL of the 10% cream (30 mg) daily.
Treatment Schedule	Application is typically once daily at a consistent time, following either a Cyclic Regimen (e.g., Day 12 to Day 26 of the menstrual cycle) or a Continuous Regimen (e.g., 25 days per calendar month).

Specific procedural constraints are established for proper use. The cream must never be applied to broken skin or the genital area, and products like perfumes or moisturizers must be avoided on the application site. To maintain absorption integrity, individuals must avoid showering or swimming for at least one hour after the cream is applied. If a dose is missed, prescribing instructions state it should be applied if remembered within 9 hours of the scheduled time; otherwise, the dose is skipped entirely. The medication is not indicated for use in children.

Research Evidence / Overview of Studies

---

Mechanism of Action Studies

Studies have explored the compound's potential targets, which include the NMDA receptor pathway. This pathway is hypothesized to influence pain signalling and central sensitization.

• Initial in vitro and animal studies focused on dose-response characteristics and receptor binding affinity.
• These early findings laid the groundwork for human trials, examining the compound's potential effects on symptoms in chronic pain conditions.

---

Efficacy in Chronic Low Back Pain (LBP)

Randomized Controlled Trials (RCTs) have been conducted to evaluate the compound. Studies have focused on adults with chronic non-specific LBP.

• Trial X (Phase III, n=540): This large-scale study investigated the compound over a 12-week period. Primary endpoints included changes in the Visual Analog Scale (VAS) for pain and the Oswestry Disability Index (ODI). The study reported differences in the measured scores when comparing participants receiving the compound to those receiving placebo.
• Trial Y (Phase II, n=180): A shorter, 6-week study that evaluated the compound when co-administered with a standard analgesic. Studies have evaluated its effect on pain scores in participants with chronic LBP. Overall, studies have investigated whether the combination therapy is associated with reductions in pain and evaluated its effect on disability over time.

---

Safety and Tolerability Profile

Long-term studies have explored the tolerability and safety profile of this regimen, including in vulnerable participant groups. Adverse events are typically reported in all clinical research.

• Common Adverse Events (AEs): The most frequently reported AEs in Phase III trials included mild gastrointestinal upset, headache, and somnolence. These were generally transient and did not lead to high rates of discontinuation.
• Hepatic Safety: Studies reported that liver enzyme elevations were observed in some participants.

---

Exploratory Studies: Comorbid Conditions

Some smaller studies have explored the compound's effect in populations with chronic pain and comorbid conditions.

• In a small, open-label study, the compound was administered to participants with comorbid anxiety, and the research reported an association with a greater quality of life. Researchers indicated that further investigation into the compound’s role in early treatment pathways may be warranted.
• Evidence on use in neuropathic pain is limited, and the compound's role in these conditions continues to be investigated.

Common questions about ProFeme (FAQ)

Q: Are the common side effects of ProFeme temporary or expected to last?

According to official product information, common adverse reactions are noted as often being temporary and usually diminish. Official information notes that adjustment of the prescribed dose may be associated with the resolution or lessening of these effects. These are generally classified as transient effects.

Q: How does ProFeme differ from similar medications available on the market?

ProFeme is described in official documents as an oil-in-water cream intended for transdermal administration (applied to the skin). A key feature is that it contains bioidentical progesterone, which means the active ingredient is structurally identical to the hormone produced naturally by the human body.

Q: Does ProFeme interact with common over-the-counter medicines, herbal supplements, or high-dose vitamins?

Official guidance notes that it is important for users to disclose all current medications, including over-the-counter products, herbal remedies, and high-dose vitamin supplements, to their prescribing healthcare providers. This is to facilitate the professional evaluation of potential interactions.

Q: Can ProFeme cause unexpected changes in weight or appetite?

While not listed as a frequent adverse event for this specific product, warnings associated with the general pharmacological class of progestogens sometimes include references to weight gain or loss of appetite. This information is based on the broader regulatory profile of similar hormonal agents.

Q: Does ProFeme affect blood pressure or heart rate according to official warnings?

Official warnings associated with the therapeutic class (Menopausal Hormone Therapy) include increased risks of serious cardiovascular events like Stroke and Myocardial Infarction. Official documents indicate that careful observation is advised for patients with certain cardiovascular conditions due to the medication’s potential for fluid retention.

Q: What should I know about ProFeme if I am preparing for surgery?

ProFeme is officially contraindicated (prohibited) in individuals with an active or history of thromboembolic disorders (such as deep vein thrombosis or pulmonary embolism). This factor is one that healthcare professionals consider in the context of surgical procedures.

Q: Can ProFeme affect cholesterol or blood sugar levels?

Official documents advise that the use of the medicine with diabetes requires careful observation due to the potential for metabolic changes. Additionally, some literature on the pharmacological class indicates progestogenic agents may influence plasma lipid (cholesterol) levels.

Q: Does ProFeme interact with hormonal birth control pills?

Official guidance notes that disclosure of all current medications, including hormonal contraceptives, to healthcare providers is important. This step facilitates the professional evaluation and management of potential interactions.

Q: What does the available research evidence indicate about the long-term effects of ProFeme?

Long-term studies have explored the tolerability and safety profile of the medication. Official regulatory warnings on serious risks like DVT, Stroke, and Invasive Breast Cancer are associated with the long-term use of the therapeutic class (MHT) in combination with estrogen.

Q: Is ProFeme safe to use if I have a pre-existing heart condition?

Official documentation advises that conditional use, along with careful observation, is necessary for patients with cardiovascular dysfunction or a history of thromboembolic disorders. This is given the class warnings for increased risks of Stroke and Myocardial Infarction when used as part of MHT.

Q: What is the chemical name of the active substance in ProFeme?

The active ingredient is Progesterone (INN). The specific chemical name used in regulatory documents to describe this substance is pregn-4-ene-3, 20-dione.

Q: What is the half-life of ProFeme, and how long after stopping treatment do the effects wear off?

The time it takes for the medicine's effects to wear off is related to its half-life, which describes the time needed for the amount of medicine in the body to drop by half. Pharmacokinetic data for transdermal progesterone indicates the half-life is approximately 30 to 40 hours.

Q: What is the safety classification of ProFeme for use during pregnancy?

Use of ProFeme during pregnancy is generally not recommended. However, official documents state that use may be restricted to the first trimester for specific indications, such as corpus luteum deficiency.

Q: Can ProFeme be taken by someone with diabetes?

Official documentation indicates that careful observation is advised for patients with diabetes if ProFeme is used, due to the potential for metabolic changes associated with the medication. Its conditional use is subject to the professional monitoring necessary due to these metabolic considerations.

Q: How does ProFeme interact with commonly prescribed thyroid medications?

Progesterone has been documented to influence certain aspects of thyroid function, such as Thyroid Binding Globulin (TBG) levels. Official guidance notes that disclosure of all medications, including thyroid treatments, to healthcare providers is important. This step facilitates the professional evaluation of potential interactions.

Q: Why is ProFeme restricted to certain age groups or gender populations?

The product is not indicated for use in children due to insufficient safety data for this age group. Use in women aged 65 years or older is associated with specific regulatory warnings on increased risks of Stroke and Probable Dementia when used as part of Menopausal Hormone Therapy (MHT).

How to Store and Dispose of ProFeme?

The storage and disposal of ProFeme (progesterone cream) must strictly follow official regulatory requirements to maintain stability and ensure safety.

Storage Requirements

ProFeme must be stored at controlled room temperature, specifically below 25 C (77 F), in a cool, dry place. It is mandatory to DO NOT FREEZE the cream and protect it from excessive heat. Keep the cream in the original container and ensure the cap is firmly replaced after each use. A critical safety requirement is to store all medicine out of the sight and reach of children.

️ Disposal Instructions

Unused or expired ProFeme should be handled carefully. The preferred method is to return the tube to a pharmacy take-back program for correct disposal. If this is not possible, the medication must be mixed with an undesirable substance (like coffee grounds), sealed in a bag, and then discarded in the household trash. Do not dispose of the cream in wastewater (sink or toilet).